peter attia on semaglutide 320 – AMA 64: New insights GLP-1 agonists (Ozempic, Wegovy, Mounjaro) - efficacy, benefits, risks, and considerations in the rapidly evolving weight-loss drug landscape dr peter attia semaglutide MD:

Common experiences during the first few weeks: Increased appetite compared to your experience on Mounjaro

These are among the largest weight-loss figures reported for any pharmacological agent in a Phase 2 obesity trial

Contact your GP or diabetes specialist to discuss your symptoms and explore appropriate management options, which may include dose adjustment or additional support

Myriad of implications of acetyl-l-carnitine deficits in depression

When you go off the drugs and then take them again, youre more likely to experience the gastrointestinal side effects again, she says, noting that these tend to lessen as you get used to the medication